Circulating DNA to Improve Outcome of Oncology PatiEnt: A Randomized Study - COPE Study
COPE is a biology driven protocol with 2 independent, multicentric, two-arm non-comparative randomized (2:1) phase II trials in 2 distinct populations: colorectal cancer patients and non-small-lung cancer patients. For each phase II trial, patient will be randomized between two arms with two patients randomized in arm A for one patient randomized in arm B: * Arm A (Experimental - initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up combining standard imaging and ctDNA analysis) * Arm B (Standard - initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up based on standard imaging).
• Age ≥ 18 years,
• Histology: colorectal cancer, non-small cell lung cancer,
• Locally advanced/unresectable and/or metastatic solid tumor,
• Eastern Cooperative Oncology Group (ECOG) performance status \< 2 (Appendix 1),
• Measurable disease according to RECIST 1.1 (lesion in previously irradiated filed can be considered as measurable if progressive at inclusion according to RECIST v1.1). At least one site of disease must be uni-dimensionally \> 10 mm,
• No previous systemic treatment for advanced disease,
• Availability of suitable paraffin embedded (FFPE) archive tumor material or at least one target lesion that can be biopsied for research purpose,
• Eligible to first-line systemic therapy,
• Patient with a social security in compliance with the French law,
⁃ Voluntary signed and dated written informed consent prior to any study specific procedure.